Tafamidis in Transthyretin Amyloid Cardiomyopathy

Amyloidosis is a group of diseases in which abnormal proteins form insoluble fibrils and deposit in tissues and organs. When these deposits occur in the heart, they can interfere with normal cardiac structure and function. Transthyretin amyloid cardiomyopathy (ATTR-CM) is an important form of cardiac amyloidosis in which transthyretin-derived amyloid fibrils accumulate mainly in the myocardium. The disease is progressive and may eventually result in restrictive cardiomyopathy and heart failure. [1,2]

Transthyretin, also called prealbumin, is a transport protein mainly produced by the liver. It is composed of 127 amino acids and normally exists as a tetramer. The protein transports thyroxine and the retinolbinding protein–vitamin A complex. Under normal conditions, the tetrameric structure is relatively stable. However, genetic variants or age-related changes can reduce this stability. [2,3]

The development of ATTR-CM can be broadly described as: TTR tetramer instability → tetramer dissociation → unstable monomers → misfolding → amyloid fibril formation → myocardial deposition → cardiac dysfunction. This process makes stabilization of the TTR tetramer an important therapeutic approach.

Tafamidis is a small-molecule TTR kinetic stabilizer. It binds to the thyroxine-binding sites of the TTR tetramer and decreases its tendency to dissociate. Therefore, tafamidis acts at an early stage of the amyloid formation pathway rather than directly removing already deposited amyloid fibrils.

[2,4]

II. Objectives of the Review

1. To explain the pathophysiology of transthyretin amyloid cardiomyopathy.

2. To describe the structure and biological role of transthyretin.

3. To explain the pharmacological properties of tafamidis.

4. To describe the mechanism of action of tafamidis.

5. To review evidence from the ATTR-ACT clinical trial.

6. To summarize evidence from systematic reviews and meta-analyses.

7. To discuss effects on mortality, hospitalization and functional capacity.

8. To describe effects on cardiac structure and biomarkers.

9. To summarize recent evidence involving cardiac scintigraphy and imaging.

10. To discuss safety, limitations and future research directions.

III. Transthyretin Amyloid Cardiomyopathy

ATTR-CM is a form of cardiac amyloidosis caused by extracellular deposition of amyloid fibrils derived from transthyretin. The accumulated amyloid material can increase myocardial wall thickness and reduce normal relaxation and filling of the heart. As the disease progresses, patients may develop restrictive cardiomyopathy and heart failure. [2,3]

ATTR-CM is generally divided into two major forms: wild-type ATTR-CM (ATTRwt-CM) and variant/hereditary ATTR-CM (ATTRv-CM). The reviewed literature describes both forms and emphasizes that genetic variants can destabilize TTR tetramers, while wild-type disease is associated with age-related instability. [2]

IV. Pathophysiology of ATTR-CM

TTR normally circulates mainly as a tetramer consisting of four identical subunits. Each monomer contains 127 amino acids. The tetramer has a central channel containing thyroxine-binding sites. [2]

The tetramer is important because the stable tetrameric form is less likely to form amyloid. The key event in amyloid formation is dissociation of the tetramer. Once dissociation occurs, unstable TTR monomers can undergo structural changes. These monomers may misfold, aggregate and form amyloid fibrils. The fibrils can then accumulate in the myocardium. [2,4]

The dissociation of the TTR tetramer is considered an important rate-limiting step in TTR amyloidogenesis. Therefore, preventing or slowing tetramer dissociation is an important therapeutic strategy. [2]

Table 1: Major Forms of Attr-Cm

Figure 1: Simple Pathway of TTR Amyloid Formation

V. Clinical Features of ATTR-CM

ATTR-CM can produce several cardiac and extracardiac manifestations. Common cardiac features include breathlessness, reduced exercise tolerance, peripheral edema, heart failure, increased ventricular wall thickness, diastolic dysfunction, arrhythmias and conduction abnormalities. Cardiac biomarkers may also be increased. [2]

Echocardiography may show increased ventricular wall thickness and reduced global longitudinal strain. ECG findings can include low voltage or a pseudo-infarction pattern. [2]

Table 2: Important Clinical Findings in Attr-Cm

VI. Diagnosis and Disease Assessment

Diagnosis may involve a combination of clinical findings, ECG, echocardiography, cardiac magnetic resonance imaging, nuclear scintigraphy and, in selected cases, tissue biopsy. [2] Nuclear imaging with technetium-labelled bone tracers can demonstrate cardiac uptake in ATTR-CM. The 2025 study included in this review used [99mTc]Tc-DPD scintigraphy and Perugini scoring to assess cardiac tracer uptake. [5]

Disease progression may be assessed using NYHA functional class, 6-minute walk test, KCCQ, NTproBNP, troponins, LVEF, global longitudinal strain, echocardiography, cardiac MRI and bone scintigraphy.

Table 3: Basic Pharmacological Profile of Tafamidis

VII. Tafamidis

Tafamidis is a small-molecule transthyretin stabilizer belonging to the 1,3-benzoxazole class. The reviewed literature identifies its chemical name as 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6carboxylic acid. [2]

Tafamidis was developed to stabilize TTR and prevent the initial step of amyloid formation. It is different from drugs that directly remove amyloid deposits; its main action is to stabilize circulating

TTR and reduce production of additional amyloid fibrils. [2]

VIII. Mechanism of Action of Tafamidis

Tafamidis binds selectively to the thyroxine-binding sites located in the central channel of the TTR tetramer. By binding to these sites, tafamidis increases the kinetic stability of the tetramer and reduces the rate at which it dissociates into monomers. [2,4]

Figure 2: Simplified Mechanism of Action of Tafamidis IX. Pharmacokinetic and Pharmacological Features

The reviewed pharmacology paper describes tafamidis as having good oral bioavailability and a relatively low toxicity profile. In healthy volunteer studies, median time to maximum concentration was approximately 2 hours and mean half-life was approximately 59 hours. [2]

The reviewed source reports that tafamidis stabilizes both wild-type and mutant TTR proteins. Tafamidis meglumine 80 mg once daily or tafamidis 61 mg once daily are described as equivalent therapeutic options for ATTR cardiomyopathy in the reviewed source. [2]

Table 4: Selected Pharmacological Characteristics

X. ATTR-ACT: Landmark Clinical Trial

The most important randomized clinical evidence for tafamidis in ATTR-CM comes from the ATTRACT trial published by Maurer and colleagues. [1] ATTR-ACT was a multicenter, international, doubleblind, placebo-controlled phase 3 study. A total of 441 patients with ATTR- CM were randomized to tafamidis 80 mg, tafamidis 20 mg or placebo for 30 months. [1]

The primary analysis assessed all-cause mortality and cardiovascular-related hospitalizations.

Secondary outcomes included changes in the 6-minute walk test and KCCQ-OS score. [1]

Table 5: Main Features of the Attr-Act Trial

Mortality: During 30 months, all-cause mortality was 29.5% with tafamidis versus 42.9% with placebo; HR 0.70 (95% CI 0.51–0.96). [1]

Cardiovascular hospitalization: The reported hospitalization rate was approximately 0.48 events/year with tafamidis versus 0.70 events/year with placebo; relative risk ratio approximately 0.68. [1] Exercise capacity and quality of life: Tafamidis was associated with slower decline in 6-minute walk distance and KCCQ-OS compared with placebo. [1]

Figure 3: Major Findings of Attr-Act

XI. Evidence from Systematic Review and Meta-analysis

A 2023 systematic review and meta-analysis searched PubMed, Ovid Embase, Scopus, Cochrane Library and Web of Science. Fifteen studies involving 2765 patients were included. Mean age was approximately 75.9 years, 83.7% were male and mean follow-up was approximately 18.7 months. [3]

Tafamidis was associated with a lower risk of all-cause death or heart transplantation (RR 0.44;

95% CI 0.31–0.65) and a lower risk of a composite adverse cardiovascular endpoint (RR 0.57; 95% CI 0.42–0.77). The analysis found no consistent significant difference in interventricular septal thickness or GLS, while the overall LVEF finding did not represent a clear deterioration in the wildtype subgroup.

[3]

XII. Evidence from the 2025 Systematic Review and Meta-analysis

A 2025 systematic review and meta-analysis included seven studies comparing tafamidis-treated and untreated patients with ATTR-CM. The review screened 976 studies from PubMed and Embase. Tafamidis was associated with lower mortality and fewer congestive heart failure exacerbations. The analysis did not find statistically significant differences in CHF hospitalization, atrial arrhythmias,

LVEF, left ventricular end-diastolic diameter or interventricular septal thickness. [4]

Table 6: Major Findings from Clinical Evidence

XIII. Real-world and Long-term Evidence

The 2024 narrative review summarized clinical trials, long-term extension studies and real-world cohorts. It reported that tafamidis treatment was associated with reductions in morbidity and mortality and slower disease progression. [7]

Real-world studies are useful because routine clinical populations may be older, have different disease severity and have more comorbidities than randomized-trial populations. However, observational studies can be affected by treatment-selection bias, confounding, differing follow-up periods and varying outcome definitions. Therefore, real-world evidence should be interpreted together with randomized trial evidence.

XIV. Tafamidis and Cardiac Imaging

Recent research has investigated whether tafamidis influences measurable structural or functional cardiac characteristics. Imaging methods include echocardiography, global longitudinal strain, cardiac magnetic resonance imaging and nuclear scintigraphy.

A 2026 systematic review reported that tafamidis was potentially associated with stabilization of global longitudinal strain and preservation of functional status. However, studies were heterogeneous and many were observational. [6]

XV. Tafamidis and [99mTc]Tc-DPD Scintigraphy

A 2025 study investigated serial [99mTc]Tc-DPD scintigraphy in 39 patients with wild-type ATTRCM receiving tafamidis. Scintigraphy was performed at baseline and during follow-up. The investigators reported significant declines in Perugini score and quantitative cardiac DPD uptake at 6 and 12 months, together with improvement in NYHA class and reduction in NT-proBNP. A reduction in right ventricular

DPD uptake at least as large as the median reduction was associated with improved survival. [5]

These findings suggest that serial nuclear imaging may provide information about treatment response, but the study was relatively small and larger prospective studies are needed before imaging can be considered a definitive marker of response. [5]

Table 7: Findings from the 2025 DPD Scintigraphy Study

XVI. Safety and Tolerability

The safety profile of tafamidis has generally been favorable in the reviewed studies. In ATTR-ACT, the incidence and types of adverse events were similar between tafamidis and placebo groups. [1] The 2021 pharmacology review also described a favorable tolerability profile. [2] A 2026 systematic review found tafamidis generally well tolerated, although safety data varied among studies. [6]

Table 8: Safety Considerations

XVII. Advantages of Tafamidis

• Disease-modifying mechanism
• TTR stabilization
• Reduced mortality in ATTR-ACT
• Reduced cardiovascular hospitalization
• Preservation of functional capacity
• Slower decline in quality of life
• Generally favorable tolerability
• Growing real-world evidence

XVIII. Limitations of Tafamidis and Current Evidence

Tafamidis stabilizes TTR but does not directly remove already deposited amyloid fibrils. Therefore, patients with advanced structural cardiac damage may not experience rapid reversal. [2]

Other limitations include delayed clinical benefit, heterogeneity among real-world studies, inconsistent findings for imaging/structural measures, and high treatment cost. The 2026 systematic review specifically noted heterogeneity and the predominance of observational evidence in much of the recent literature. [6,7]

XIX. Recent Evidence: 2023–2026

Figure 4: Development of Evidence for Tafamidis

The evidence base has continued to expand. The 2023 meta-analysis synthesized 15 studies and 2765 patients. The 2024 narrative review integrated clinical trials and real-world evidence. In 2025, a metaanalysis reported lower mortality and CHF exacerbations, while a separate imaging study reported reduced DPD uptake. A 2026 systematic review incorporated 17 studies and 1890 patients and evaluated mortality, function, biomarkers and imaging. [3-7]

XX. Comparison of Major Evidence Sources

Table 9: Summary of Important Tafamidis Studies

DISCUSSION

ATTR-CM is a progressive disease in which the underlying molecular problem involves instability and dissociation of TTR tetramers. Tafamidis targets this process by stabilizing the tetramer rather than directly removing amyloid. [2]

The strongest evidence for clinical efficacy comes from ATTR-ACT, which demonstrated reductions in mortality and cardiovascular hospitalization and slower decline in exercise capacity and quality of life.

[1] Subsequent systematic reviews generally support these findings. [3,4]

Recent imaging evidence provides an additional research direction. The 2025 DPD scintigraphy study reported reductions in cardiac tracer uptake after tafamidis treatment. [5] If confirmed in larger prospective studies, imaging may help monitor disease progression and response.

The 2026 systematic review reported potential preservation of global longitudinal strain and functional status, but also emphasized heterogeneity. [6] Thus, current evidence is strongest for major clinical outcomes, while imaging and biomarker evidence remains an evolving area.

XXII. Future Perspectives

Earlier diagnosis before extensive cardiac damage.

Development of biomarkers that more directly reflect amyloid burden or treatment response.

Further validation of serial nuclear imaging and strain imaging.

Long-term studies in different ATTR subtypes and disease stages.

Research on combination strategies that address different stages of the amyloid pathway.

Improved affordability and access to disease-modifying therapy.

CONCLUSION

Transthyretin amyloid cardiomyopathy is a progressive disease caused by deposition of misfolded transthyretin amyloid fibrils in the heart. Dissociation of the TTR tetramer is an important step in amyloid formation.

Tafamidis is a TTR kinetic stabilizer that binds to thyroxine-binding sites and reduces tetramer dissociation. ATTR-ACT demonstrated reduced all-cause mortality and cardiovascular hospitalization and slower decline in exercise capacity and quality of life. [1]

Subsequent systematic reviews and meta-analyses have generally supported these findings. Recent studies have expanded the evidence to cardiac strain, biomarkers and nuclear imaging. [3-7] Overall, tafamidis represents an important disease-modifying approach for ATTR-CM. Early diagnosis, longterm follow-up and further research into disease monitoring and amyloid regression remain important.

XXIV. Key Points for Pharmacy Students

1. ATTR-CM is caused by deposition of transthyretin amyloid in the heart.

2. TTR normally exists as a tetramer.

3. Tetramer dissociation is an important step in amyloid formation.

4. Tafamidis is a TTR kinetic stabilizer.

5. It binds to the thyroxine-binding site of TTR.

6. It reduces TTR tetramer dissociation and formation of new amyloid fibrils.

7. ATTR-ACT showed reduced mortality and cardiovascular hospitalization.

8. Tafamidis also slows decline in exercise capacity and quality of life.

9. Recent studies are investigating biomarkers and imaging as measures of treatment response.

10. Tafamidis is generally well tolerated in the reviewed studies.

11. It does not directly remove already deposited amyloid.

REFERENCES

1. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379 (11):1007-1016. doi:10.1056/NEJMoa1805689.
2. Kim D, Choi J-O, Jeon E-S. Tafamidis for cardiac transthyretin amyloidosis. Cardiovasc Prev Pharmacother. 2021;3:e1.
3. Wang J, Chen H, Tang Z, Zhang J, Xu Y, Wan K, et al. Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis. EClinicalMedicine. 2023;63:102172.
4. Hussain B, Duhan S, Patel B, Chang Y-C, Hamza M, Najam M, et al. Tafamidis: A game changer in transthyretin cardiomyopathy? A systematic review and meta-analysis of safety and efficacy. Curr Probl Cardiol. 2025;50 (9):103129.
5. Ungericht M, Schuetz T, Messner M, Puelacher C, Staggl S, Zaruba M-M, et al. Effects of tafamidis on serial [99mTc]Tc-DPD scintigraphy in transthyretin amyloid cardiomyopathy. Eur J Nucl Med Mol Imaging. 2025;52:2529-2537. doi:10.1007/s00259-025-07092-7.
6. Nasser A, Michalczak M, Malkowski A, Zgoda WM, Michalczak J, Ządło A, Tokarek T. Tafamidis in the contemporary management of transthyretin cardiac amyloidosis: a systematic review. J Clin Med. 2026;15:5832.
7. Ogieuhi IJ, Ugiomoh OM-A, Muzofa K, Callender K, Ayodeji JD, Nnekachi NP, et al. Tafamidis therapy in transthyretin amyloid cardiomyopathy: a narrative review from clinical trials and realworld evidence. Egypt Heart J. 2024;76:90. doi:10.1186/s43044-024-00517-y.
8. Brunton LL, Hilal-Dandan R, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw Hill; 2023. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 16th ed. New York: McGraw Hill; 2024.
9. Ritter JM, Flower RJ, Henderson G, Loke YK, MacEwan DJ, Rang HP. Rang & Dale’s Pharmacology. 10th ed. Elsevier; 2023.
10. Lemke TL, Williams DA, Roche VF, Zito SW. Foye’s Principles of Medicinal Chemistry. 8th ed. Wolters Kluwer; 2019.
11. Wilson CO, Gisvold O. Wilson and Gisvold’s Textbook of Organic Medicinal and Pharmaceutical Chemistry. 12th ed. Wolters Kluwer. Katzung BG, Trevor AJ. Katzung & Trevor’s Pharmacology Examination & Board Review. 13th ed. McGraw Hill; 2021.
12. B. Tafamidis / ATTR-CM Research and Review Articles Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. New England Journal of Medicine. 2018;379:1007– 1016.
13. Rapezzi C, Quarta CC, Riva L, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nature Reviews Cardiology
14. Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin Amyloid Cardiomyopathy. Journal of the American College of Cardiology.
15. Kittleson MM, Maurer MS, Ambardekar AV, et al. Cardiac Amyloidosis: Evolving Diagnosis and Management. Circulation. Maurer MS, Elliott P, Merlini G, et al. Clinical Trials and Therapeutic Approaches in Transthyretin Amyloid Cardiomyopathy. Journal of the American College of Cardiology.
16. Ruberg FL, Berk JL. Transthyretin (TTR) Cardiac Amyloidosis. Circulation. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients withtransthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379 (11):1007-1016. doi:10.1056/NEJMoa1805689.
17. Kim D, Choi J-O, Jeon E-S. Tafamidis for cardiac transthyretin amyloidosis. Cardiovasc Prev Pharmacother. 2021;3:e1.
18. Wang J, Chen H, Tang Z, Zhang J, Xu Y, Wan K, et al. Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy: asystematic review and meta-analysis. EClinicalMedicine. 2023;63:102172. doi:10.1016/j.eclinm.2023.102172.
19. Hussain B, Duhan S, Patel B, Chang Y-C, Hamza M, Najam M, et al. Tafamidis: A game changer in transthyretin cardiomyopathy?A systematic review and meta-analysis of safety and efficacy. Curr Probl Cardiol. 2025;50 (9):103129.
20. Ungericht M, Schuetz T, Messner M, Puelacher C, Staggl S, Zaruba M-M, et al. Effects of tafamidis on serial [99mTc]Tc-DPDscintigraphy in transthyretin amyloid cardiomyopathy. Eur J Nucl Med Mol Imaging. 2025;52:2529-2537. doi:10.1007/s00259-025-07092-7.
21. Nasser A, Michalczak M, Malkowski A, Zgoda WM, Michalczak J, Z■d■o A, Tokarek T. Tafamidis in the contemporary management of transthyretin cardiac amyloidosis: a systematic review. J Clin Med. 2026;15:5832.
22. Ogieuhi IJ, Ugiomoh OM-A, Muzofa K, Callender K, Ayodeji JD, Nnekachi NP, et al. Tafamidis therapy in transthyretin amyloidcardiomyopathy: a narrative review from clinical trials and realworld evidence. Egypt Heart J. 2024;76:90. doi:10.1186/s43044-024-00517-y.
23. Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve. 2007;36:411-423. doi:10.1002/mus.20821.
24. Johnson SM, Connelly S, Fearns C, Powers ET, Kelly JW. The transthyretin amyloidoses: from delineating the molecularmechanism of aggregation linked to pathology to a regulatory agency approved drug. J Mol Biol. 2012;421:185-203. doi:10.1016/j.jmb.2011.12.060.
25. Bulawa CE, Connelly S, DeVit M, Wang L, Weigel C, Fleming JA, et al. Tafamidis, a potent and selective transthyretin kineticstabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A. 2012;109:9629-9634. doi:10.1073/pnas.1121005109.
26. Hammarström P, Jiang X, Hurshman AR, Powers ET, Kelly JW. Sequence-dependent denaturation energetics: a majordeterminant in amyloid disease diversity. Proc Natl Acad Sci U S A. 2002;99:16427-16432.
27. Hammarström P, Wiseman RL, Powers ET, Kelly JW. Prevention of transthyretin amyloid disease by changing protein misfoldingenergetics. Science. 2003;299:713-716.
28. Sekijima Y, Wiseman RL, Matteson J, Hammarström P, Miller SR, Sawkar AR, et al. The biological and chemical basis fortissue-selective amyloid disease. Cell. 2005;121:73-85. doi:10.1016/j.cell.2005.01.018.
29. Saelices L, Johnson LM, Liang WY, Sawaya MR, Cascio P, Ruchala P, et al. Uncovering the mechanism of aggregation of humantransthyretin. J Biol Chem. 2015;290:28932-28943.
30. Vieira M, Saraiva MJ. Transthyretin: a multifaceted protein. Biomol Concepts. 2014;5:45-54. doi:10.1515/bmc-2013-0038.
31. Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy. J Am Coll Cardiol.2019;73:2872-2891. doi:10.1016/j.jacc.2019.04.003.
32. Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, et al. Cardiac amyloidosis: evolvingdiagnosis and management. Circulation. 2020;142:e7-e22. doi:10.1161/CIR.0000000000000792.
33. Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M, et al. Expert consensus recommendations for the suspicionand diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail. 2019;12:e006075. doi:10.1161/CIRCHEARTFAILURE.119.006075.
34. Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a positionstatement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42:1554-1568.
35. Bistola V, Parissis J, Foukarakis E, Valsamaki PN, Anastasakis A, Koutsis G, et al. Practical recommendations for the diagnosisand management of transthyretin cardiac amyloidosis. Heart Fail Rev. 2021;26:861-879. doi:10.1007/s10741-020-10062-w.
36. Yamamoto H, Yokochi T. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. ESC Heart Fail.2019;6:1128-1139. doi:10.1002/ehf2.12518.
37. Gertz MA, Benson MD, Dyck PJ, Grogan M, Coats CJ, Hopkins PN, et al. Diagnosis, prognosis, and therapy of transthyretinamyloidosis. J Am Coll Cardiol. 2015;66:2451-2466. doi:10.1016/j.jacc.2015.09.075.
38. Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, et al. Natural history of wildtype transthyretin cardiac amyloidosisand risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68:1014-1020. doi:10.1016/j.jacc.2016.06.033.
39. Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Verkkoniemi A, et al. Senile systemic amyloidosis affects 25% ofthe very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med. 2008;40:232-239. doi:10.1080/07853890701842988.
40. Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, et al. Left ventricular amyloid deposition in patientswith heart failure and preserved ejection fraction. JACC Heart Fail. 2014;2:1-10.
41. González-López E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, CoboMarcos M, Robles C, et al. Wild-typetransthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36:2585-2594.
42. Castaño A, Narotsky DL, Hamid N, Khalique OK, Morgenstern R, DeLuca A, et al. Unveiling transthyretin cardiac amyloidosis andits predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017;38:2879-2887.
43. Ternacle J, Krapf L, Mohty D, Magne J, Nguyen A, Galat A, et al. Aortic stenosis and cardiac amyloidosis: JACC review topic of theweek. J Am Coll Cardiol. 2019;74:2638-2651. doi:10.1016/j.jacc.2019.09.056.
44. Sperry BW, Reyes BA, Ikram A, Donnelly JP, Phelan D, Jaber WA, et al. Tenosynovial and cardiac amyloidosis in patientsundergoing carpal tunnel release. J Am Coll Cardiol. 2018;72:2040-2050. doi:10.1016/j.jacc.2018.07.092.
45. Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, et al. Genotype and phenotype of transthyretin cardiacamyloidosis: THAOS registry. J Am Coll Cardiol. 2016;68:161-172.
46. Rapezzi C, Quarta CC, Riva L, Longhi S, Gallelli I, Lorenzini M, et al. Transthyretin-related amyloidoses and the heart: a clinicaloverview. Nat Rev Cardiol. 2010;7:398-408.
47. Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012;126:12861300.
48. Ruberg FL, Maurer MS. Cardiac amyloidosis due to transthyretin protein: a review. JAMA. 2024;331:778-791. doi:10.1001/jama.2024.0442.
49. Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387:26412654.
50. Gertz MA, Dispenzieri A. Systemic amyloidosis recognition, prognosis, and therapy: a systematic review. JAMA. 2020;324:79-89.
51. Buxbaum JN, Dispenzieri A, Eisenberg DS, et al. Amyloid nomenclature 2022: update, novel proteins, and recommendations bythe International Society of Amyloidosis Nomenclature Committee. Amyloid. 2022;29:213-219. doi:10.1080/13506129.2022.2147636.
52. Westermark P, Benson MD, Buxbaum JN, Cohen AS, Frangione B, Ikeda S, et al. A primer of amyloid nomenclature. Amyloid.2007;14:179-183.
53. Perugini E, Guidalotti PL, Salvi F, Cooke RMT, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosisusing 99mTc-DPD scintigraphy. J Am Coll Cardiol. 2005;46:1076-1084.
54. Gillmore JD, Reilly MM, Nicholl P, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation.2016;133:2404-2412.
55. Bokhari S, Castano A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. 99mTc-pyrophosphate scintigraphy for differentiatinglight-chain cardiac amyloidosis from transthyretin-related cardiac amyloidosis. Circ Cardiovasc Imaging. 2013;6:195-201.
56. Castaño A, Haq M, Narotsky DL, Goldsmith J, Weinberg RL, Moran JV, et al. Multicenter study of planar technetium 99mpyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol. 2016;1:880-889.
57. Phelan D, Collier P, Thavendiranathan P, Popovic ZB, Hanna M, Plana JC, et al. Relative apical sparing of longitudinal strain intransthyretin cardiac amyloidosis. Heart. 2012;98:1442-1448.
58. Murtagh B, Hammill SC, Gertz MA, Kyle RA, Tajik AJ, Grogan M. Electrocardiographic findings in primary systemic amyloidosisand biopsy-proven cardiac involvement. Am J Cardiol. 2005;95:535-537.
59. Cyrille NB, Goldsmith J, Alvarez J, Maurer MS. Prevalence and prognostic significance of low QRS voltage among the three maintypes of cardiac amyloidosis. Am J Cardiol. 2014;114:10891093. doi:10.1016/j.amjcard.2014.07.026.
60. Banypersad SM, Fontana M, Maestrini V, Sado DM, Captur G, Petrie A, et al. T1 mapping and survival in systemic light-chainamyloidosis. Eur Heart J. 2015;36:244-251.
61. Fontana M, Banypersad SM, Treibel TA, Maestrini V, Sado DM, White SK, et al. Native T1 mapping in transthyretin amyloidosis.JACC Cardiovasc Imaging. 2014;7:157-165.
62. Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, et al. Cardiovascular magnetic resonance in cardiacamyloidosis. Circulation. 2005;111:186-193.
63. Moon JC, Reed E, Sheppard MN, Elkington AG, Ho SY, Burke M, et al. The histologic basis of late gadolinium enhancementcardiovascular magnetic resonance in aortic stenosis. J Am Coll Cardiol. 2004;44:1441-1448.
64. Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Boos CJ, et al. Prognostic value of late gadolinium enhancementcardiovascular magnetic resonance in cardiac amyloidosis. J Cardiovasc Magn Reson. 2015;17:57.
65. Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Zumbo G, Knight DS, et al. Magnetic resonance in transthyretin cardiacamyloidosis. J Am Coll Cardiol. 2017;70:466-477.
66. Martinez-Naharro A, Hawkins PN, Fontana M. Cardiac amyloidosis. Clin Med (Lond). 2018;18:s30-s35.
67. Maurer MS, Elliott P, Merlini G, Shah SJ, Cruz MW, Flynn A, et al. Addressing common challenges in the diagnosis andmanagement of cardiac amyloidosis: a scientific statement. J Am Coll Cardiol. 2021;77:1810-1837.
68. Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC cardiac amyloidosis practice points: 99mTc-PYPimaging for transthyretin cardiac amyloidosis. J Nucl Cardiol. 2019;26:2065-2071.
69. Kittleson MM, Maurer MS, Ambardekar AV, et al. 2025 ACC concise clinical guidance for transthyretin cardiac amyloidosisevaluation and management. J Am Coll Cardiol. 2026;87:549565. doi:10.1016/j.jacc.2025.09.004.
70. Maurer MS, Grogan DR, Judge DP, et al. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilizationand clinical outcomes. Circ Heart Fail. 2015;8:519-526. doi:10.1161/CIRCHEARTFAILURE.114.001942.
71. Damy T, Judge DP, Kristen AV, Berthet K, Li H, Aarts J. Cardiac findings and events observed in an open-label clinical trial oftafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis. J Cardiovasc Transl Res. 2015;8:117-127.
72. Merlini G, Plante-Bordeneuve V, Judge DP, et al. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patientswith non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res. 2013;6:1011-1020.
73. Damy T, Judge DP, Kristen AV, et al. Efficacy and safety of tafamidis doses in the ATTR-ACT and long-term extension study. Eur JHeart Fail. 2021;23:277-290. doi:10.1002/ejhf.2027.
74. Elliott P, et al. Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy. Circulation.2022;145:145-156.
75. Maurer MS, et al. Improved long-term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy andsevere heart failure symptoms. Eur J Heart Fail. 2023.
76. Lockwood PA, Le VH, O'Gorman MT, et al. The bioequivalence of tafamidis 61-mg free acid capsules and tafamidis meglumine 4 ×20-mg capsules in healthy volunteers. Clin Pharmacol Drug Dev. 2020;9:849-854. doi:10.1002/cpdd.789.
77. Cruz MW, Benson MD. A review of tafamidis for the treatment of transthyretin-related amyloidosis. Neurol Ther. 2015;4:61-79. doi:10.1007/s40120-015-0031-3.
78. Waddington Cruz M, et al. Tafamidis: a review in transthyretin amyloidosis with polyneuropathy. Drugs. 2019;79:189-201.
79. Patil MB, Ghode P, Joshi P. A comprehensive review on chemistry and biology of tafamidis in transthyretin amyloidosis. Mini RevMed Chem. 2024;24:571-587. doi:10.2174/0113895575241556231003055323.
80. Nawarskas JJ, Shephard EA. Tafamidis: a novel treatment for transthyretin amyloid cardiomyopathy. Cardiol Rev. 2020;28:55-60. doi:10.1097/CRD.0000000000000306.
81. Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol.2015;66:2451-2466.
82. Manion C, Sharma UC. Tafamidis for transthyretin amyloid cardiomyopathy. N Engl J Med. 2019;380:196.
83. Le Bras A. Tafamidis: a new treatment for ATTR cardiomyopathy. Nat Rev Cardiol. 2018;15:652.
84. Rigopoulos AG, Ali M, Abate E, et al. Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiacinvolvement. Heart Fail Rev. 2019;24:521-533.
85. Specific therapy for transthyretin cardiac amyloidosis: a systematic literature review and evidence-based recommendations. J ClinMed. 2021;10:493.
86. Kazi DS, Bellows BK, Baron SJ, et al. Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy.Circulation. 2020;141:1214-1224. doi:10.1161/CIRCULATIONAHA.119.045093.
87. Lau K, Kim K, et al. Cost-effectiveness of systematic screening and treatment of transthyretin amyloid cardiomyopathy in patientswith HFpEF. Int J Cardiol. 2024;410:131598. doi:10.1016/j.ijcard.2023.131598.
88. Modeling the cost and health impacts of diagnostic strategies in patients with suspected transthyretin cardiac amyloidosis. CircCardiovasc Qual Outcomes. 2022.
89. Kao TW, et al. Effect of tafamidis on clinical and functional parameters in transthyretin amyloid cardiomyopathy. JACC Adv. 2025.
90. Tafamidis efficacy in transthyretin amyloid cardiomyopathy: a systematic review and metaanalysis. 2024.
91. Transthyretin stabilizer targeting for transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis. 2025.
92. Merlo M, et al. Tafamidis in the treatment of ATTR-related cardiomyopathy: indications and grey zones. Heart Fail Clin. 2024. doi:10.1016/j.hfc.2024.03.007.
93. Izumiya Y, Kuyama N, Hanatani S, Matsuzawa Y, Usuku H, Yamamoto E, et al. Realworld clinical evidence with tafamidis inpatients with transthyretin amyloid cardiomyopathy: a contemporary review. Circ Rep. 2025;7.
94. Kuyama N, et al. Long-term effect of tafamidis on clinical parameters and prognostic predictors in patients with transthyretinamyloid cardiomyopathy. Circ J. 2025. doi:10.1253/circj.CJ-24-0733.
95. Ochi Y, et al. Clinical characteristics, outcome, and therapeutic effect of tafamidis in wildtype transthyretin amyloidcardiomyopathy. ESC Heart Fail. 2023;10:2622-2634. doi:10.1002/ehf2.14380.
96. Multiparametric monitoring of disease progression in contemporary patients with wildtype transthyretin amyloid cardiomyopathyinitiating tafamidis treatment. 2024.
97. Impact of tafamidis on myocardial function and CMR tissue characteristics in transthyretin amyloid cardiomyopathy. ESC HeartFail. 2024.
98. Tafamidis decreased cardiac amyloidosis deposition in patients with Ala97Ser hereditary transthyretin cardiomyopathy: a 12-monthfollow-up cohort study. 2023.
99. CMR-based assessment of long-term effects of tafamidis in patients with cardiac transthyretin amyloidosis. 2026.
100. Improvements in efficacy measures with tafamidis in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial. 2024.
101. The effect of long-term tafamidis treatment on quality of life in people with transthyretin amyloid cardiomyopathy. 2024.
102. Real-world outcomes in cardiac transthyretin amyloidosis and association with New York Heart Association class. 2024.
103. Garcia-Pavia P, Kristen AV, Drachman B, et al. Long-term survival and tafamidis treatment in transthyretin amyloidcardiomyopathy: THAOS real-world evidence. 2025.
104. Wixner J, Dispenzieri A, Amass L, et al. A real-world study of tafamidis in people with transthyretin amyloid cardiomyopathy withheart and nerve symptoms. 2026.
105. Nativi-Nicolau J, et al. Transthyretin amyloidosis: clinical spectrum and treatment approaches. 2020.
106. Ando Y, Coats CJ, Nativi-Nicolau J, et al. Clinical approach to hereditary transthyretin amyloidosis. 2022.
107. Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol. 2005;62:1055-1059.
108. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin-mediatedamyloidosis. N Engl J Med. 2018;379:11-21.
109. Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl JMed. 2018;379:22-31.
110. Adams D, Tournev IL, Taylor MS, et al. HELIOS-A: vutrisiran in patients with hereditary transthyretin-mediated amyloidosis withpolyneuropathy. Amyloid. 2023.
111. Gillmore JD, Reilly MM, Stewart M, et al. Vutrisiran in transthyretin amyloidosis with cardiomyopathy. N Engl J Med.2025;392:33-44.
112. Fontana M, Berk JL, Gillmore JD, et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N Engl J Med.2025;392:33-44.
113. Gillmore JD, Judge DP, Cappelli F, et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med.2024;390:132-142.
114. Judge DP, Nativi-Nicolau J, Maurer MS, et al. Transthyretin stabilization and diseasemodifying therapy in ATTR cardiomyopathy.2020.
115. Kristen AV, Ajroud-Driss S, Damy T, et al. Monitoring disease progression and treatment response in transthyretin amyloidosis.2021.
116. Gillmore JD, Damy T, Reilly MM, et al. Eplontersen in hereditary transthyretin amyloidosis. N Engl J Med. 2024.
117. Bukhari S. Cardiac amyloidosis: state-of-the-art review. J Geriatr Cardiol. 2023;20:361375. doi:10.26599/1671-5411.2023.05.006.
118. Bukhari S, Oliveros E, Parekh H, Farmakis D. Epidemiology, mechanisms, and management of atrial fibrillation in cardiacamyloidosis. Curr Probl Cardiol. 2023;48:101571.
119. Giancaterino S, Urey MA, Darden D, Hsu JC. Management of arrhythmias in cardiac amyloidosis. JACC Clin Electrophysiol.2020;6:351-361.
120. Shetty NS, Pampana A, Patel N, Maurer MS, Goyal P, Li P, et al. Carpal tunnel syndrome and transthyretin amyloidosis in the Allof Us Research Program. Mayo Clin Proc. 2024;99:11011111.
121. Kwok CS, Moody WE. The importance of pathways to facilitate early diagnosis and treatment of patients with cardiac amyloidosis.Ther Adv Cardiovasc Dis. 2023;17:17539447231216318.
122. Aljaroudi WA, Desai MY, Tang WH, Phelan D, Cerqueira MD, Jaber WA. Role of imaging in the diagnosis and management ofpatients with cardiac amyloidosis: state of the art review and focus on emerging nuclear techniques. J Nucl Cardiol. 2014;21:271-283.